These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Beneficial effects of simvastatin may be due to non-lipid actions. Ravnskov U BMJ; 1995 Nov; 311(7017):1436-7. PubMed ID: 8520302 [No Abstract] [Full Text] [Related]
44. [Therapeutic possibilities of a newly registered lipid suppressor]. Mölgaard J; Olsson AG Lakartidningen; 1988 Oct; 85(40):3271-4. PubMed ID: 3199954 [No Abstract] [Full Text] [Related]
45. Lowering patients' cholesterol. Extrapolating results of trial of simvastatin gives room for doubt. Hippisley-Cox J BMJ; 1995 Sep; 311(7006):690-1. PubMed ID: 7549665 [No Abstract] [Full Text] [Related]
46. [Current developments in prevention of coronary heart disease]. Windler E Z Arztl Fortbild (Jena); 1996 Feb; 90(1):7-10. PubMed ID: 8650967 [TBL] [Abstract][Full Text] [Related]
47. [Primary and secondary prevention of coronary disease by statins]. Ferrières J Ann Cardiol Angeiol (Paris); 1999 Feb; 48(2):128-36. PubMed ID: 12555337 [TBL] [Abstract][Full Text] [Related]
48. [Therapeutic trial of simvastatin versus fenofibrate in primary hypercholesterolemia]. Turki S; Mekaouer A; Kaabachi A; Ftouhi B; Mebazaa R; Ben Khalifa F Tunis Med; 1994 Nov; 72(11):619-24. PubMed ID: 7762089 [No Abstract] [Full Text] [Related]
49. Modulation of coronary endothelial function by lovastatin. Misra A Natl Med J India; 1995; 8(6):271-2. PubMed ID: 8520448 [No Abstract] [Full Text] [Related]
50. The 4S study and its pharmacoeconomic implications. Reckless JP Pharmacoeconomics; 1996 Feb; 9(2):101-5. PubMed ID: 10172696 [No Abstract] [Full Text] [Related]
51. Cholesterol lowering does have a role in secondary prevention. Wood DA Br Heart J; 1995 Jan; 73(1):4-5. PubMed ID: 7888259 [No Abstract] [Full Text] [Related]
52. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658 [TBL] [Abstract][Full Text] [Related]
53. A clinical focus on statins. Auer J; Eber B Curr Opin Investig Drugs; 2001 Mar; 2(3):382-8. PubMed ID: 11575709 [TBL] [Abstract][Full Text] [Related]
54. [Use of hydroxymethylglutaryl coenzyme A reductase inhibitors in patients with post-transplantation hyperlipemia]. Martínez-Castelao A Med Clin (Barc); 1995 Nov; 105(18):719. PubMed ID: 8538262 [No Abstract] [Full Text] [Related]
55. [The cholesterol hypothesis has been proved true at last]. Huttunen J Duodecim; 1995; 111(5):385-6. PubMed ID: 8674438 [No Abstract] [Full Text] [Related]
56. Hypercholesterolemia treatment in a renal transplant patient. Devuyst O; Goffin E; Pirson Y; van Ypersele de Strihou C Clin Nephrol; 1994 May; 41(5):319. PubMed ID: 8050214 [No Abstract] [Full Text] [Related]
57. [Even at LDL cholesterol 100mg/dl. "Every coronary disease patient has to receive a statin"]. MMW Fortschr Med; 2003 Dec; 145(49):57. PubMed ID: 14963997 [No Abstract] [Full Text] [Related]
58. Petechial eruptions due to simvastatin in a patient with diabetes mellitus and liver cirrhosis. Horiuchi Y; Maruoka H J Dermatol; 1997 Aug; 24(8):549-51. PubMed ID: 9301152 [No Abstract] [Full Text] [Related]
59. Twenty-four more days. Goldstein MR Am J Cardiol; 1998 Sep; 82(5):703-4. PubMed ID: 9732913 [No Abstract] [Full Text] [Related]
60. Nephrotic syndrome and simvastatin. Thomas M; Moorhead JF Lancet; 1990 Jun; 335(8701):1344-5. PubMed ID: 1971403 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]